IA
BTAI icon

IndexIQ Advisors’s BioXcel Therapeutics BTAI Stock Holding History

IndexIQ Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-612
Closed -$199K – 1335
2021
Q4 		$199K Sell
612
-39
-6% -$16.7K 0.01% 1032
2021
Q3 		$316K Buy
651
+65
+11% +$28.6K 0.01% 971
2021
Q2 		$272K Sell
586
-24
-4% -$13.1K 0.01% 995
2021
Q1 		$422K Buy
+610
New +$491K 0.01% 446

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IndexIQ Advisors's BTAI Position: Q1 2022 in Review

IndexIQ Advisors sold out of BioXcel Therapeutics (BTAI) in Q1 2022, closing a stake of 612 shares — an estimated $199K sold.

IndexIQ Advisors first reported a position in BTAI in Q1 2021 and held it in 4 quarters. The position peaked at $422K in Q1 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2022.

  • IndexIQ Advisors reported no remaining BioXcel Therapeutics position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 612 BioXcel Therapeutics shares in Q1 2022, an estimated $199K.
  • IndexIQ Advisors first reported a position in BioXcel Therapeutics in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's BioXcel Therapeutics position peaked at $422K in Q1 2021.
  • 96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.